{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:20:49Z","timestamp":1789737649886,"version":"4.0.1"},"reference-count":19,"publisher":"American Association for Cancer Research (AACR)","issue":"2","funder":[{"DOI":"10.13039\/100007345","name":"University of Arizona Cancer Center","doi-asserted-by":"publisher","award":["CA023074"],"award-info":[{"award-number":["CA023074"]}],"id":[{"id":"10.13039\/100007345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007345","name":"University of Arizona Cancer Center, and NCI","doi-asserted-by":"publisher","award":["P01CA027502"],"award-info":[{"award-number":["P01CA027502"]}],"id":[{"id":"10.13039\/100007345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prevention of nonmelanoma skin cancers remains a health priority due to high costs associated with this disease. Diclofenac and difluoromethylornithine (DFMO) have demonstrated chemopreventive efficacy for cutaneous squamous cell carcinomas. We designed a randomized study of the combination of DFMO and diclofenac in the treatment of sun-damaged skin. Individuals with visible cutaneous sun damage were eligible. Subjects were randomized to one of the three groups: topical DFMO applied twice daily, topical diclofenac applied daily, or DFMO plus diclofenac. The treatment was limited to an area on the left forearm, and the duration of use was 90 days. We hypothesized that combination therapy would have increased efficacy compared with single-agent therapy. The primary outcome was change in karyometric average nuclear abnormality (ANA) in the treated skin. Individuals assessing the biomarkers were blinded regarding the treatment for each subject. A total of 156 subjects were randomized; 144 had baseline and end-of-study biopsies, and 136 subjects completed the study. The ANA unexpectedly increased for all groups, with higher values correlating with clinical cutaneous inflammation. Nearly all of the adverse events were local cutaneous effects. One subject had cutaneous toxicity that required treatment discontinuation. Significantly more adverse events were seen in the groups taking diclofenac. Overall, the study indicated that the addition of topical DFMO to topical diclofenac did not enhance its activity. Both agents caused inflammation on a cellular and clinical level, which may have confounded the measurement of chemopreventive effects. More significant effects may be observed in subjects with greater baseline cutaneous damage. Cancer Prev Res; 9(2); 128\u201334. \u00a92015 AACR.<\/jats:p>\n               <jats:p>See related article by Tsai and Hawk, p. 125<\/jats:p>","DOI":"10.1158\/1940-6207.capr-15-0232","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T03:34:02Z","timestamp":1451360042000},"page":"128-134","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm"],"prefix":"10.1158","volume":"9","author":[{"given":"Joanne M.","family":"Jeter","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Curiel-Lewandrowski","sequence":"additional","affiliation":[{"name":"2Division of Dermatology, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Stratton","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Myrdal","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Warneke","sequence":"additional","affiliation":[{"name":"4Department of Surgery, University of Arizona College of Medicine, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine G.","family":"Einspahr","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G.","family":"Bartels","sequence":"additional","affiliation":[{"name":"5Department of Pathology, University of Arizona College of Medicine, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yozwiak","sequence":"additional","affiliation":[{"name":"5Department of Pathology, University of Arizona College of Medicine, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yira","family":"Bermudez","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Hu","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics, University of Arizona College of Public Health, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bartels","sequence":"additional","affiliation":[{"name":"7Optical Sciences Center, College of Optical Sciences, University of Arizona, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Alberts","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"2022060816324992800_bib1","article-title":"Cancer Facts & Figures 2015","author":"American Cancer Society","year":"2015"},{"key":"2022060816324992800_bib2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archderm.136.12.1524","article-title":"Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis","volume":"136","author":"Marcil","year":"2000","journal-title":"Arch Dermatol"},{"key":"2022060816324992800_bib3","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrc1454","article-title":"Polyamines and cancer: old molecules, new understanding","volume":"4","author":"Gerner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2022060816324992800_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1053\/j.gastro.2010.06.005","article-title":"Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"2022060816324992800_bib5","first-page":"1281","article-title":"Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine","volume":"9","author":"Alberts","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060816324992800_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1940-6207.CAPR-09-0096","article-title":"A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer","volume":"3","author":"Bailey","year":"2010","journal-title":"Cancer Prev Res"},{"key":"2022060816324992800_bib7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/carcin\/19.5.723","article-title":"COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer","volume":"19","author":"Buckman","year":"1998","journal-title":"Carcinogenesis"},{"key":"2022060816324992800_bib8","first-page":"1335","article-title":"Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma","volume":"30","author":"Asgari","year":"2004","journal-title":"Dermatol Surg"},{"key":"2022060816324992800_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00403-005-0601-9","article-title":"Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies","volume":"297","author":"Pirard","year":"2005","journal-title":"Arch Dermatol Res"},{"key":"2022060816324992800_bib10","first-page":"401","article-title":"Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze)","volume":"3","author":"Nelson","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"2022060816324992800_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical diclofenac in hyaluronan gel for the treatment of solar keratoses","volume":"44","author":"Gebauer","year":"2003","journal-title":"Australas J Dermatol"},{"key":"2022060816324992800_bib12","first-page":"429","article-title":"New and emerging treatments for nonmelanomas and actinic keratoses","volume":"2","author":"Peterson","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"2022060816324992800_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","article-title":"Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial","volume":"1","author":"Meyskens","year":"2008","journal-title":"Cancer Prev Res"},{"key":"2022060816324992800_bib14","first-page":"149","article-title":"Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer","volume":"8","author":"Einspahr","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2022060816324992800_bib15","first-page":"285","article-title":"Reliability and validity of a histologic score as a marker for skin cancer chemoprevention studies","volume":"25","author":"Bozzo","year":"2003","journal-title":"Anal Quant Cytol Histol"},{"key":"2022060816324992800_bib16","first-page":"341","article-title":"Toward objective prognostic grading of prostatic carcinoma using image analysis","volume":"15","author":"Irinopoulou","year":"1993","journal-title":"Anal Quant Cytol Histol"},{"key":"2022060816324992800_bib17","first-page":"62","article-title":"Malignancy-associated changes in the breast. Changes in chromatin distribution in epithelial cells in normal-appearing tissue adjacent to carcinoma","volume":"17","author":"Susnik","year":"1995","journal-title":"Anal Quant Cytol Histol"},{"key":"2022060816324992800_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/sim.4780080703","article-title":"Regression with an ordered categorical response","volume":"8","author":"Hastie","year":"1989","journal-title":"Stat Med"},{"key":"2022060816324992800_bib19","first-page":"17","article-title":"Progression of skin lesions from normal skin to squamous cell carcinoma","volume":"31","author":"Krouse","year":"2009","journal-title":"Anal Quant Cytol Histol"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/9\/2\/128\/2255776\/128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/9\/2\/128\/2255776\/128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T18:53:19Z","timestamp":1654714399000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/9\/2\/128\/50509\/Phase-IIB-Randomized-Study-of-Topical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-15-0232","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}